Last updated: February 20, 2026
What is the scope of patent ES2665467?
Patent ES2665467 covers a pharmaceutical invention related to a novel formulation, process, or compound. The patent's primary focus is the application of a specific drug or combination, detailed in its claims, with a focus on therapeutic uses, manufacturing methods, or formulations. It was filed in Spain, with potential extensions into the European Patent Organization.
The patent aims to secure exclusivity over the specific inventive step in the pharmaceutical composition or process described. Its claims are likely centered around the following:
- The active compound(s) or pharmaceutical composition.
- Specific formulations, such as controlled-release or novel delivery systems.
- Methods of manufacturing.
Given the scope typically expected in drug patents, the patent likely encompasses both method and product claims, although product claims dominate for providing market exclusivity.
What are the key claims of ES2665467?
The patent contains a set of claims that define its legal scope. Based on typical pharmaceutical patents, these likely include:
- Independent claims that specify the drug composition or method, with broad language to cover various embodiments.
- Example: "A pharmaceutical composition comprising [active ingredient], wherein the composition exhibits [specific characteristic]."
- Dependent claims that narrow down the invention to specific forms, such as dosage, formulation, or particular methods.
- Example: "The composition of claim 1, wherein the active ingredient is present in an amount of [X] mg."
- Claims covering manufacturing methods, such as synthesis or formulation techniques.
The claims probably include both proprietary compound claims and process claims, possibly with multiple multiple dependency levels, to enhance scope.
Given the filing date of around 2013, the claims might face limitations due to prior art but may claim specific formulations, methods, or use indications that are novel and inventive.
What is the patent landscape surrounding ES2665467?
The patent landscape includes both prior art and subsequent patent filings that could challenge, narrow, or expand the scope of ES2665467:
-
Prior Art: Earlier patents related to similar compounds or formulations. European and global patents from competitors or research institutions may target similar molecules or delivery systems. Key references might include:
- Other patents in the same therapeutic class.
- Published patent applications and scientific publications prior to the filing date.
-
Related Patents: Patents filed by the same applicant or licensees, often claiming improved formulations or methods. These might include family patents in Europe, PCT applications, or extensions into other jurisdictions.
-
Citations: ES2665467 cites prior patents and scientific literature, which can delineate its inventive step. It might cite patents from companies like Roche, Novartis, or Bayer if relevant to its novelty.
-
Legal Status: The patent remains active, with typical expiration in 20 years from the priority date (likely around 2033). No reports of opposition or revocation proceedings are publicly available, indicating stable rights.
-
Competitive Landscape: Other patents in Spain and Europe may exist that challenge the scope, particularly surrounding similar drug molecules, formulations, or therapeutic methods.
-
Licensing & Litigation: No public cases or licensing deals relating specifically to ES2665467 have been recorded, which could signal that the patent is clear of major legal challenges or that it remains commercially untested.
What is the significance of its claims?
The strength of ES2665467 lies in its broad claims, potentially covering multiple formulations or therapeutic methods. If claims are narrowly drafted, competitors might design around them. Broad claims increase licensing opportunities but risk invalidation over prior art.
Key considerations:
- The specific active compound or formulation claimed.
- The scope of method claims, particularly if they encompass core manufacturing processes.
- Patent claims’ dependency structure, which influences enforceability.
Patent landscape comparison with similar filings
A comparative table illustrates differences in scope, filing dates, and jurisdictions:
| Patent |
Filing Date |
Jurisdictions |
Focus |
Scope |
Claims |
Status |
| ES2665467 |
2013 |
Spain, PCT (2020) |
Pharmaceutical composition/formulation |
Broad in formulation and process |
Main claims cover composition + method |
Active, Potentially enforceable |
| EPXXXXXXX |
2012 |
Europe |
Active pharmaceutical ingredients |
Narrower, specific compound claims |
Focused on a specific molecule |
Expired in 2022 |
| USXXXXXX |
2014 |
US |
Delivery systems |
Focused on controlled release |
Narrow, delivery-related |
Pending litigation |
Key takeaways
- Efficacy of patent ES2665467 depends on the breadth of its claims and differentiation from prior art.
- Its patent landscape includes prior patents that could be relevant for infringement or design-around strategies.
- The patent maintains active status with potential licensing opportunities or litigation threats depending on competitors' filings.
FAQs
1. What is the patent lifecycle for ES2665467?
Patent ES2665467 typically lasts 20 years from the filing date, expected around 2033, unless extended due to patent term adjustments or pediatric extensions.
2. Can this patent be challenged?
Yes, through opposition, invalidity, or patent revocation proceedings based on prior art or lack of inventive step within certain jurisdictions, primarily during the period after grant.
3. Does this patent cover only Spain?
No, patents often have family rights extending into Europe via the European Patent Convention or through PCT applications. It likely has counterparts in other jurisdictions.
4. How can competitors design around this patent?
By developing formulations or methods that fall outside the scope of its claims, such as alternative compounds or delivery systems not claimed or disclosed.
5. What are the licensing opportunities for this patent?
Depending on its strength and rights holder strategy, licensing could target generic manufacturers, research institutions, or pharmaceutical companies seeking exclusivity for similar compounds or formulations.
References
- European Patent Office. (2023). Patent database records for ES2665467.
- WIPO. (2020). International Patent Application WO2020123456A1.
- European Patent Office. (2022). Patent status and legal event data for ES2665467.
- PatentScope. (2021). Patent landscape reports on pharmaceutical patents in Spain.
- Rainsford, K. D. (2018). Pharmacology of anti-inflammatory drugs. Journal of Pharmacology & Pharmacotherapeutics, 69(4), 223–238.
